Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib
Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative
Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling
Transduction Analysis (FACT-2)